Delphinus Medical Technologies, Inc., innovator and developer of the SoftVue™ whole breast ultrasound tomography system, has secured an additional $11 million through a combination of equity and debt financing. Delphinus has filed for clearance with the U.S. Food and Drug Administration and this latest round of funding will further the development of the technology and support commercialization efforts when cleared.

Arboretum Ventures of Ann Arbor, Mich. and Beringea, LLC of Farmington Hills, Mich. co-led this series and are joined by North Coast Technology Investors. The addition of debt venture completed this round.

'We believe Delphinus is poised to create real change in breast cancer detection with the SoftVue technology,' commented Paul McCreadie, managing director of Arboretum Ventures. 'We look forward to our continued partnership with the Delphinus team in their successful commercial initiatives.'

'We're very pleased and appreciative to have the continued backing of our investor community, supporting our efforts toward commercialization. We're confident that our SoftVue technology will make a difference for women facing breast disease and for those in the medical professions who care for them. With this latest round of funding, we look forward to bringing this technology to the market for the benefit of women who need it,' said Bill Greenway, CEO of Delphinus.

'We continue to realize the value and potential this innovative technology has to advance the detection of breast cancer and are pleased to have the opportunity to continue our support as Delphinus moves ahead to commercialization,' said Michael Gross, managing director of Beringea.

The SoftVue technology was invented by Peter Littrup, M.D. and Neb Duric, Ph.D., of the Karmanos Cancer Institute and Wayne State University. In 2009, Karmanos Cancer Institute spun off Delphinus Medical Technologies to bring this advanced imaging to the marketplace. Studies have shown SoftVue has the potential to improve breast cancer diagnosis, aiding radiologists by optimizing reflection, sound speed, and attenuation characteristics. The development plan highlights future advancements beyond diagnosis, to interventional techniques for biopsy and screening.

About Delphinus Medical Technologies, Inc.
Delphinus Medical Technologies, Inc., a Michigan-based company, is a spin-off of the Barbara Ann Karmanos Cancer Institute (KCI). The patented technology is a whole breast ultrasound tomography imaging device that provides no radiation, no compression, and is not dependent on operator skills. Delphinus Medical Technologies holds the UST intellectual property, transferred by KCI through a worldwide license to commercialize the SoftVue technology.

SoftVue has not received market clearance from the FDA at this time.

About Arboretum Ventures
Arboretum Ventures is a venture capital firm specializing in the healthcare sector. More than simply a financial resource, Arboretum is a collaborative, value-added investor actively engaging their portfolio companies in strategy, operations, recruiting, fundraising, and exit planning. Arboretum aims to transform young companies into mature and thriving businesses that improve patient outcomes and lower the cost of care, thereby generating superior returns for the entrepreneurs and our investors. Founded in 2002 and headquartered in Ann Arbor, Michigan, Arboretum currently manages approximately $235 million in capital. For more information, please visit www.arboretumvc.com.

About Beringea
Beringea, LLC provides equity and/or mezzanine debt to small- and-middle market companies. Founded in 1988, the Firm is headquartered in Farmington Hills, Michigan with an affiliate office in London, UK. Beringea invests in portfolio companies operating in a range of sectors, including health care, clean technology, advanced manufacturing, media, Internet technologies and specialized consumer products. With flexible capital solutions, extensive investing experience and offices in the U.S. and UK, Beringea's team offers its portfolio companies the resources to grow their businesses and create value for shareholders. For more information, visit www.beringea.com.

In the United States of America, Beringea operates as an SEC-registered investment advisor, Beringea LLC. In the United Kingdom, this document is issued by Beringea LLP, a firm authorized and regulated by the Financial Conduct Authority. Beringea LLP is a limited liability partnership registered in England and Wales with company number OC342919, and its registered office is at 39 Earlham Street, London, WC2H 9LT, UK. This document is intended solely to provide information regarding Beringea's potential financing capabilities for prospective portfolio companies.

About North Coast Technology Investors
North Coast Technology Investors LP is a venture capital firm with approximately $100 million under management that actively invests in technology-driven companies at their earliest stages. North Coast's goal is to back entrepreneurs who seek to build transformative enterprises in the Midwest. For more information about North Coast, please call 734-662-7667 or visit www.northcoastvc.com.

About the Barbara Ann Karmanos Cancer Institute Located in mid-town Detroit, MI, the Barbara Ann Karmanos Cancer Institute is one of 40 National Cancer Institute-designated comprehensive cancer centers in the U.S. Caring for nearly 6,000 new patients annually on a budget of $216 million, conducting more than 700 cancer-specific scientific investigation programs and clinical trials, Karmanos is among the nation's best cancer centers. Through the commitment of 1,000 staff, including nearly 300 physicians and researchers on faculty at the Wayne State University School of Medicine, and supported by thousands of volunteer and financial donors, Karmanos strives to prevent, detect and eradicate all forms of cancer. Its long-term partnership with the WSU School of Medicine enhances the collaboration of critical research and academics related to cancer care. Gerold Bepler, M.D., Ph.D., is the Institute's president and chief executive officer. Karmanos is southeastern Michigan's most preferred hospital for cancer care according to annual surveys conducted by the National Research Corporation. For more information call 1-800-KARMANOS or go towww.karmanos.org.